- Home
- Political Science
- American Government
- Emerging Issues in Biomedical Policy: An Annual Review (Setting Allocation Priorities)
Emerging Issues in Biomedical Policy: An Annual Review (Setting Allocation Priorities)
List Price:
$42.00
- Availability: Confirm prior to ordering
- Branding: minimum 50 pieces (add’l costs below)
- Check Freight Rates (branded products only)
Branding Options (v), Availability & Lead Times
- 1-Color Imprint: $2.00 ea.
- Promo-Page Insert: $2.50 ea. (full-color printed, single-sided page)
- Belly-Band Wrap: $2.50 ea. (full-color printed)
- Set-Up Charge: $45 per decoration
- Availability: Product availability changes daily, so please confirm your quantity is available prior to placing an order.
- Branded Products: allow 10 business days from proof approval for production. Branding options may be limited or unavailable based on product design or cover artwork.
- Unbranded Products: allow 3-5 business days for shipping. All Unbranded items receive FREE ground shipping in the US. Inquire for international shipping.
- RETURNS/CANCELLATIONS: All orders, branded or unbranded, are NON-CANCELLABLE and NON-RETURNABLE once a purchase order has been received.
Product Details
Author:
Robert H. Blank, Andrea L. Bonnicksen
Format:
Paperback
Pages:
315
Publisher:
Columbia University Press (December 16, 1993)
Imprint:
Columbia University Press
Language:
English
Audience:
Professional and scholarly
ISBN-13:
9780231074117
ISBN-10:
0231074115
Weight:
15.84oz
Dimensions:
6" x 9"
File:
TWO RIVERS-PERSEUS-Metadata_Only_Perseus_Distribution_Customer_Group_Metadata_20260328163254-20260328.xml
Folder:
TWO RIVERS
List Price:
$42.00
Case Pack:
36
As low as:
$32.34
Publisher Identifier:
P-PER
Discount Code:
A
Overview
Volume 1 discusses the problems inherent in allocating limited biomedical technologies: whose needs take precedence, what individual rights and responsibilities are involved, and when societal good justifies restricting individual good. Volume Two focuses on two substantive areas of biomedical policy beset by conflicts. Physicians, patients, and public officials are locked in new battles over whether and when life-extending technologies should be used or withdrawn. Meanwhile, researchers, government officials, and patients struggle to determine who will receive experimental medical treatment, and what procedures should be instituted to protect the recipients.
